Mogrify
The company develops a novel class of in vivo reprogramming therapies designed to restore organ function by identifying transcriptomic and epigenetic switches required for direct cellular conversion. Its proprietary MOGRIFY and epiMOGRIFY platforms leverage transcriptomic and epigenetic data to identify transcription factors for converting or maintaining cell identity. The technology initially targets indications in otology, ophthalmology, and diabetes to address high unmet clinical needs.
Biotechnology
Healthcare
Regenerative Medicine
Healthtech
Funding summary
- Total raised
- €37.6M
- Funding rounds
- 3
Investors in Mogrify
Investors on record for Mogrify. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Mogrify?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors